MGO One Seven’s Acadia Pharmaceuticals ACAD Stock Holding History

MGO One Seven’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$3K	Hold	112	–	–	﹤0.01%	1415
2017 Q4	$3K	Buy	+112	New	+$3.58K	﹤0.01%	1412

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

MGO One Seven's ACAD Position: Q1 2018 in Review

MGO One Seven held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2018 at 112 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

MGO One Seven first reported a position in ACAD in Q4 2017 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

MGO One Seven held 112 shares of Acadia Pharmaceuticals worth $3K as of Q1 2018.
MGO One Seven left its Acadia Pharmaceuticals share count unchanged in Q1 2018.
Acadia Pharmaceuticals made up ﹤0.01% of MGO One Seven's portfolio in Q1 2018, its #1415 holding.
MGO One Seven first reported a position in Acadia Pharmaceuticals in Q4 2017 and has held it in 2 quarters since.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on MGO One Seven's 13F filing for Q1 2018, filed 15 May 2018.